Advertisement

Topics

Lynparza Poised For Growth With Broad Ovarian Cancer Approval

16:45 EDT 17 Aug 2017 | SCRIP

AstraZeneca's Lynparza now has the broadest US label of all PARP inhibitors for ovarian cancer, as well as competitive dosing...

      

Related Stories

 

Original Article: Lynparza Poised For Growth With Broad Ovarian Cancer Approval

NEXT ARTICLE

More From BioPortfolio on "Lynparza Poised For Growth With Broad Ovarian Cancer Approval"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...